Steven Deeks, MD

Headshot of Steven Deeks
User Profile Photo

Steven Deeks, MD

User Profile Name
Co-Director, Clinical Core
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.

Dr. Deeks has published over 650 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants and is the contact principal investigator of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection. He recently directed the amfAR Institute for HIV Cure Research. In early 2020, he leveraged his HIV research program to construct the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, which is now supporting dozens of studies addressing the impact of SARS-CoV-2 on health.

Dr. Deeks is a member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He serves on the scientific advisory board for Science Translational Medicine and is the editor-in-chief of Current Opinion in HIV and AIDS. Based on a recent study conducted at Stanford, he is among the top 0.01% of all scientists, based on citations, adjusted for authorship position and impact, and has been listed by Clarivite as one of the world's most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF.

In addition to his translational and clinical. investigation, Dr. Deeks maintains a primary care clinic for people living with HIV.

User Profile Bio

Displaying 301 - 325 of 668

  1. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015 Jan 15; 517(7534):381-5.
  2. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015 Jan 02; 29(1):43-51.
  3. Somsouk M, Dunham RM, Cohen M, Albright R, Abdel-Mohsen M, Liegler T, Lifson J, Piatak M, Gorelick R, Huang Y, Wu Y, Hsue PY, Martin JN, Deeks SG, McCune JM, Hunt PW. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One. 2014; 9(12):e116306.
  4. Hollingsworth TD, Pilcher CD, Hecht FM, Deeks SG, Fraser C. High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California. J Infect Dis. 2015 Jun 01; 211(11):1757-60.
  5. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014 Oct; 10(10):e1004473.
  6. Deeks S. Towards an HIV cure. J Int AIDS Soc. 2014; 17(4 Suppl 3):19479.
  7. Deeks SG, Siliciano R. HIV Prevention and Treatment Fields Join Forces. EBioMedicine. 2014 Nov; 1(1):4-5.
  8. Sanchez JL, Hunt PW, Reilly CS, Hatano H, Beilman GJ, Khoruts A, Jasurda JS, Somsouk M, Thorkelson A, Russ S, Anderson J, Deeks SG, Schacker TW. Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. J Infect Dis. 2015 Apr 1; 211(7):1068-75.
  9. Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, Strain MC, Chomont N, Hecht FM, Siliciano RF, Richman DD, Deeks SG. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS One. 2014; 9(10):e110731.
  10. Cockerham LR, Deeks SG. Biomarker reveals HIV's hidden reservoir. Elife. 2014 Oct 16; 3:e04742.
  11. Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Somsouk M, Hunt PW, Deeks SG, Nixon DF, SenGupta D. The CD8⁺ memory stem T cell (T(SCM)) subset is associated with improved prognosis in chronic HIV-1 infection. J Virol. 2014 Dec; 88(23):13836-44.
  12. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, Bangsberg DR, Yiannoutsos CT, Deeks SG, Martin JN. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014 Sep 10; 28(14):2097-107.
  13. Klatt NR, Bosinger SE, Peck M, Richert-Spuhler LE, Heigele A, Gile JP, Patel N, Taaffe J, Julg B, Camerini D, Torti C, Martin JN, Deeks SG, Sinclair E, Hecht FM, Lederman MM, Paiardini M, Kirchhoff F, Brenchley JM, Hunt PW, Silvestri G. Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals. PLoS Pathog. 2014 Aug; 10(8):e1004345.
  14. Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014; 11:27.
  15. Borges ÁH, Weitz JI, Collins G, Baker JV, Lévy Y, Davey RT, Phillips AN, Neaton JD, Lundgren JD, Deeks SG, INSIGHT SILCAAT Scientific Committee . Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS. 2014 Jul 31; 28(12):1791-6.
  16. Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, Hunt PW, Martin JN, Pilcher CD, Sekaly R, McCune JM, Hecht FM, Deeks SG. Programmed death-1 expression on CD4? and CD8? T cells in treated and untreated HIV disease. AIDS. 2014 Jul 31; 28(12):1749-58.
  17. Deeks SG, Hunt PW. Antiretroviral therapy: stubborn limitations persist. Lancet. 2014 Jul 19; 384(9939):214-6.
  18. Lewin SR, Deeks SG, Barré-Sinoussi F. Towards a cure for HIV--are we making progress? Lancet. 2014 Jul 19; 384(9939):209-11.
  19. Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, Chakraborty R, Batra J, Kosalaraksa P, Luesomboon W, Porter D, Shao Y, Myers M, Ting L, SenGupta D, Quirk E, Rhee MS. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016 12; 3(12):e561-e568.
  20. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014 Jul 11; 345(6193):169-74.
  21. Li P, Fujimoto K, Bourguingnon L, Yukl S, Deeks S, Wong JK. Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells. Immunol Cell Biol. 2014 Oct; 92(9):770-80.
  22. Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, Cockerham LR, Pilcher CD, Hecht FM, Sinclair E, Liegler T, Richman DD, Deeks SG, Pillai SK. Decreased HIV type 1 transcription in CCR5-?32 heterozygotes during suppressive antiretroviral therapy. J Infect Dis. 2014 Dec 01; 210(11):1838-43.
  23. Rakhi P. Naik, Marguerite R. Irvin, Suzanne Judd, Orlando Gutierrez, Neil A Zakai, Vimal K. Derebail, Carmen Peralta, Michael Lewis, Degui Zhi, Donna Arnett, William McClellan, James G. Wilson, Alexander Reiner, Jeffrey Kopp, Cheryl Winkler, Mary Cushman. Association of Hemoglobin S and C Traits with Kidney Disease in African Americans in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Blood. 2015 Dec 3; 126(23):70-70.
  24. Rachael P. Jackman, Douglas Bolgiano, Mila Lebedeva, Sherrill J. Slichter, Philip J. Norris. C1q-Binding HLA Antibodies Do Not Predict Platelet Transfusion Failure in TRAP Study Participant. Blood. 2014 Dec 6; 124(21):1562-1562.
  25. Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT, AIDS Clinical Trials Group A5296 Team . Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15; 210(10):1549-54.